JLK said on the 30th that its solution that analyzes brain hemorrhage images with artificial intelligence (AI) received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA). It helps clinicians diagnose cerebrovascular diseases and degenerative conditions.
JLK's solution analyzes brain susceptibility-weighted MRI (magnetic resonance imaging). The company said it allows clinicians to identify small lesions and shorten the time until patients receive treatment.
The company plans to strengthen cooperation with a Japanese distributor. Kim Dong-min, CEO of JLK, said, "We will distribute the solution to Japanese university hospitals and medical institutions going forward."
※ This article has been translated by AI. Share your feedback here.